So I think something that was not discussed locally but noted on the Cantor note (thanks @Anjo-Roch) was that MSB provided the FDA with additional data from Mt Sinai which was using current standard of care, and in a sort of retrospective analysis reiterated that remestemscel was effective. Perhaps someone with more technical knowledge can comment on that? But maybe that's what the US took out of it and hence the rise as it further increases probability of success. Us Aussie schmucks just saw a delay as the takeaway.
Ann: MSB Files GvHD Clinical Efficacy and Safety Data with US FDA, page-61
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.010(0.92%) |
Mkt cap ! $1.233B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.11 | $1.05 | $5.002M | 4.632M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5697 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
-0.010 ( 0.10 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.11 | $1.06 | 1181223 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| MSB (ASX) Chart |